Changchun High-Tech (000661.SZ) subsidiary's GenSci155 injection clinical trial application approved

Zhitong Finance APP News, Changchun High-Tech (000661.SZ) announced that recently, its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical") received the Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration. The domestic production drug registration clinical trial application for Jinsai Pharmaceutical's GenSci155 injection has been approved. The drug is intended for the prevention of bronchopulmonary dysplasia (BPD) in premature infants and the treatment of primary insulin-like growth factor-1 deficiency (PIGFD), with subcutaneous injection as the route of administration.